Hold residual BMY exposure for dividend carry; binding 9/21 reflection prohibits adding into broken momentum below 50 SMA
Hold residual BMY exposure for the 4% covered dividend carry (1.6x FCF coverage on $8.1B TTM FCF) and 0.23-beta structural floor. The 9/21 binding reflection is dispositive: do NOT upgrade sizing at $63.88 — buying into broken momentum (price 0.8% below 50 SMA at $64.42, MACD still bearish, RSI ~50 unconfirmed) leaks alpha regardless of position sizing. Hard stop $55. Re-engage on confirmed 50 SMA reclaim at $64.42 with volume >15M AND MACD bullish cross AND RSI >50, OR on pullback to $58-60 near 200 SMA at $58.49 with RSI <35 and no further downside acceleration. The aggressive analyst's valuation case (forward PE 9.7x, 4% covered yield) is compelling but timing-prohibited; the conservative analyst's concerns (Eliquis LOE, debt refinancing drag) are real but floor integrity is intact per 9/17 reflection. Honest adjusted PEG of ~1.5-2.5 justifies maintaining exposure but not adding. Recent Hold track record (9/22: +1.3%, 9/23: +0.7%, 9/24: +1.7%, 9/25: +2.4%) validates patience with covered yield and intact floor optionality.
| Position | Action |
|---|---|
| Current configuration (price below 50 SMA at $64.42, MACD bearish, RSI ~50 unconfirmed) | Maintain residual exposure; do NOT upgrade sizing |
| Aggressive analyst proposed 50-75% deployment at $63.88 | Rejected — violates 9/21 binding reflection; alpha leakage determined by entry into broken momentum, not by sizing |
| Neutral analyst proposed 30-35% pilot at $63.88 | Rejected — still violates 9/21 binding reflection in substance |
BMY is an anomalously cheap defensive pharma name trading at 9.7x forward PE with a 4%+ dividend yield, 0.23 beta, and a growing new product portfolio (Cobenfy, ZENBEXUS, arlo-cel) that is already reflecting in Q2 2026's +5.7% revenue growth, making the HOLD recommendation materially too conservative given the asymmetric risk/reward and clustered catalysts.
| Indicator | Value | Signal |
|---|---|---|
| Close | $63.88 | neutral |
| 200 SMA | $58.49 | bullish |
| 50 SMA | $64.42 | bearish |
| 10 EMA | $63.01 | bullish |
| RSI | 50.29 | neutral |
| MACD | -0.65 | bearish |
| MACD Signal | -0.454 | bearish |
| Bollinger Middle | $64.22 | bearish |
| Bollinger Upper | $68.26 | bullish |
| Bollinger Lower | $60.18 | bullish |
| ATR | $1.35 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Pullback to $58-60 near 200 SMA at $58.49 with RSI <35 holding AND no further downside acceleration
Then: Deploy capital in $58-60 range
Q2 2026 demonstrates the pivot from patent cliff is already working
↩ rebuts: “Bear patent cliff overhang concern”
EV: +$5-10% near-term (to $66-68); +13-18% on multiple expansion (to $72-75) · concedes: $45B debt and $39.4B goodwill with negative tangible book value represent real impairment risks (though Q4 2025 worst-case already absorbed); Eliquis (~30% of revenue) faces IRA drug pricing pressure post-2026; Revlimid continues to decline post-LOE; Patent cliff was a legitimate concern (now largely navigated)
BMY is a value trap where the low valuation appropriately reflects structural headwinds including an accelerating patent cliff on Eliquis (~30% of revenue), ongoing Revlimid generic erosion, a fragile balance sheet with $45B debt and negative tangible book value, and pipeline assets that remain commercially unproven.
· concedes: The Q2 2026 +5.7% growth did occur (though characterized as single-quarter bounce vs. trend); Income investors who already own the stock should hold for the dividend; Existing holders should collect the dividend and use rallies to $66-68 as rebalancing opportunities
→ vs conservative: PEG ratio of 17.5 is not a legitimate red flag because it is mechanically distorted by $1.58 billion in one-time Q4 2025 restructuring charges; stripping this non-recurring impairment reveals underlying earnings power at 9.73x forward PE that represents deep value, not overvaluation — anyone anchoring to a PEG that includes phantom charges is anchoring to a phantom
→ vs conservative: Patent cliff thesis misses that the replacement story is already visible in the numbers — Q2 2026 revenue grew 5.7% despite Revlimid erosion, Cobenfy is launching into a schizophrenia market that hasn't seen a new mechanism in decades, and the company raised its full-year 2026 sales outlook in July; the market is pricing a cliff that has been largely digested while ignoring pipeline delivering today
→ vs conservative: Higher-for-longer rate concern is already maximally priced at 97% probability of zero Fed cuts in 2026 on Polymarket — there is no incremental hawkish surprise left to deliver; 4% dividend yield with 0.23 beta is the exact profile that thrives in this macro backdrop, not one that gets punished
→ vs neutral: 50 SMA concern at 64.42 is a rounding error — price is only 54 cents below on a stock with $1.35 ATR; the 10 EMA at $63.01 has already turned up, RSI has rocketed 17.7 points in four sessions, and ATR compression 25% signals imminent volatility expansion to the upside
→ vs neutral: MACD bearish signal is being given too much weight when the 200 SMA at $58.49 has held with price 9.2% above it — the long-term uptrend is fully intact and colleagues are 'staring at a fifty-four cent technical wobble while ignoring the nine percent structural cushion underneath'
→ vs neutral: Waiting for 'confirmation' at $58-60 pullback before committing meaningful capital means potentially missing the FDA decision entirely — a binary catalyst that could send the stock to $70+ immediately; waiting for textbook setups in the presence of clustered catalysts is the definition of leaving money on the table
Support: 60.18 · 62 · 63.01 · 58.49 | Resistance: 64.22 · 64.42 · 66.05 · 68.26
BMY is in a confirmed long-term uptrend with the 200 SMA at $58.49 providing structural support, having risen from $54.43 over two months. The medium-term trend turned bearish as price fell below the 50 SMA ($64.42), which has now flattened, creating bearish divergence against rising price. A short-term reversal is in progress with price reclaiming the 10 EMA ($63.01) and RSI recovering from oversold 32.61 to 50.29, while MACD remains below the signal line at -0.454 but the histogram gap is narrowing, suggesting fading selling momentum. Key resistance sits at the Bollinger Middle ($64.22) and 50 SMA ($64.42), with strong resistance at $68.26 (Bollinger Upper), while support zones are anchored at the 200 SMA ($58.49) and Bollinger Lower ($60.18).
Market Cap
$130.49 billion
PE Ratio (TTM)
14.07
Forward PE
9.73
PEG Ratio
17.50
Price/Book
5.85
Dividend Yield
4.01%
Beta
0.227
Operating Margin (TTM)
34.42%
Net Profit Margin (TTM)
18.87%
Gross Margin
71.7%
Return on Equity (ROE)
46.6%
Return on Assets (ROA)
10.72%
EPS (TTM)
$4.54
Forward EPS
$6.56
Book Value/Share
$10.93
Total Assets
$87.63 billion
Goodwill & Intangibles
$39.37 billion
Tangible Book Value
-$17.05 billion
Net PP&E
$9.28 billion
Cash & Equivalents
$8.72 billion
Receivables
$12.99 billion
Total Debt
$45.05 billion
Net Debt
$34.40 billion
Current Debt
$1.23 billion
Long-term Debt
$42.09 billion
Stockholders' Equity
$22.32 billion
Debt-to-Equity
2.02x (201.86%)
Net Debt/EBITDA (TTM)
1.82x
Current Ratio
1.53
Working Capital
$9.92 billion
Working Capital YoY Change
+74%
Free Cash Flow (TTM)
$8.11 billion
Operating Cash Flow (Q2 2026)
$3.39 billion
Capital Expenditures (Q2 2026)
$305 million
Dividends Paid (Q2 2026)
$1.287 billion
FCF Payout Ratio
63%
Treasury Stock
$43.5 billion
Q2 2026 Revenue
$12.97 billion
Q2 2026 Revenue YoY Growth
+5.7%
Q2 2026 Operating Income
$4.03 billion
Q2 2026 Operating Income YoY Growth
+6.7%
Q2 2026 Net Income
$3.32 billion
Q2 2026 Diluted EPS
$1.62
Q1 2026 Revenue YoY Growth
-6.4%
Q4 2025 Restructuring Charges
$1.58 billion
52-Week High
$68.64
52-Week Low
$42.52
50-Day Moving Average
$64.35
200-Day Moving Average
$59.14
Retained Earnings
$20.32 billion
Strengths
Concerns
HOLD — BMY offers compelling deep value (Forward PE 9.73x) with a high dividend yield (4.01%) and low beta (0.227), but faces significant risks from $39.4B in goodwill/intangibles, high leverage ($45B debt), and weak near-term growth visibility (PEG 17.5); Q2 2026 showed accelerating revenue (+5.7% YoY) and strong FCF ($8.11B TTM) driven by Eliquis, Opdivo, and newly-launched Cobenfy/Krazati, though the stock has already rallied ~50% off its 52-week low, limiting near-term upside and warranting accumulation on dips below the 200-day MA at $59.14 or a breakout above the 52-week high at $68.64.
Macro: Higher-for-longer rates dominate with Polymarket showing 97% probability of zero Fed rate cuts in 2026, reinforcing defensive appeal of BMY's ~5% dividend yield versus money-market alternatives; Kevin Warsh hawkish signal and rising 10-year yields creating mild multiple compression risk for defensive dividend payers; US recession probability at 8% (+2 pp WoW) worth monitoring but still below critical 15-20% threshold.